Affiliation:
1. Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, PLA General Hospital, Beijing, China
2. PLA Medical School, Beijing, China
Abstract
Background. To explore the use of teicoplanin among Chinese patients with Gram-positive infections in a tertiary hospital. Methods. The medical records of patients, who were monitored for teicoplanin plasma concentration (TPC) from December 2017 to February 2019, were collected. By combining the therapeutic drug monitoring (TDM) and nonlinear mixed-effects model, a population pharmacokinetic (PPK) model of teicoplanin was established. Results. The proportions of TPCs lower and higher than 10 mg/L were nearly the same (102 vs. 108 cases). A two-compartment model of teicoplanin PPK in Chinese patients was established. Compared with 400 mg, the 600 mg regimen was more able to reach the target concentration (10 mg/L), especially for high-weight patients. Conclusions. The standard regimen of teicoplanin, 400 mg, failed to reach the target value in the present population. Moreover, the 600 mg regimen was feasible for high-weight patients based on TDM and individualized pharmacokinetic dosing adjustment.
Funder
National Natural Science Foundation of China
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. The continuing threat of methicillin-resistant staphylococcus aureus;M. Gajdács;Antibiotics (Basel, Switzerland),2019
2. The use of vancomycin with its therapeutic and adverse effects: a review;F. R. Bruniera;European Review for Medical and Pharmacological Sciences,2015
3. Clinical Pharmacokinetics of Teicoplanin
4. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy;S. H. Kim;European Journal of Clinical Microbiology & Infectious Diseases,2019
5. Comparative Pharmacokinetics of Teicoplanin and Vancomycin